Lucio C Rovati

This inventor holds 59 USPTO granted patents and 6 published patent applications, plus 3 CIPO patents and 24 EPO patents, primarily in Pharmaceutical Innovations (CPC class C07D). Top assignees: Rottapharm Spa, Rottapharm Biotech S.r.l., Rotta Research Laboratorium. Active years: 1988-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Lucio C Rovati. Retrieved from https://idiyas.com/inventor/lucio-c-rovati

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 59 (Patent Applications = 6)

% Patents Active = 45.8

CIPO Patents = 3 (Patent Applications = 2)

EPO Patents = 24 (Patent Applications = 27)

Average Co-Inventor Count = 3.7

ph-index = 7

Forward Citations = 231(Granted Patents)

Forward Citations (Not Self Cited) = 219(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Milan, IT (2015)
Monza, IT (1988 - 2023)

Company Filing History:

Rottapharm Biotech S.r.l.

patents

15 out of 33

Rotta Research Laboratorium

patents

4. 2 out of 2

Rotta Research Laboratories S.p.a.

Rotta Research Laboraturium S.p.a.

Years Active: 1988-2026

Loading Chart...

Areas of Expertise:

EP4 Antagonists

Kinase Inhibitors

Anti-Inflammatory Agents

Pharmaceutical Combinations

Quinazoline Derivatives

Analgesics

Immunosuppressive Activity

Neuroprotective Agents

Silibinin

Hyaluronic Acid Esters

COX-2 Inhibitors

Orexin Receptor Antagonists

59 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12544365 - Pharmaceutical combination of an EP4 antagonist and immune checkpoint inhibitors for the treatment of tumours (2026-02-10),

2. 12509446 - FYN and VEGFR2 kinase inhibitors (2025-12-30),

3. 12433875 - (R)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro[2.5]octane-5-carboxamido)-cyclopropyl) benzoic acid or its salt also in polymorphic form a for use in the prevention of heterotopic ossification (2025-10-07),

4. 12404245 - Process for the preparation of (R)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro[2.5]octane-5-carboxamido)-cyclopropyl) benzoic acid or a salt thereof (2025-09-02),

5. 11718582 - (R)-4-(1-(1-(4-(trifluoromethyl)benzyl)pyrrolidine-2-carboxamide)cyclopropyl)-benzoic acid as EP4 receptor antagonist (2023-08-08),

6. 11590114 - Pharmaceutical combination of an EP4 antagonist and immune checkpoint inhibitors for the treatment of tumours (2023-02-28),

7. 10125121 - FYN kinase inhibitors (2018-11-13),

8. 9631029 - Anti-ADAMTS-5 antibody, derivatives and uses thereof (2017-04-25),

9. 9498478 - Spiro aminic compounds with NK1 antagonist activity (2016-11-22),

10. 9493438 - 4,4-difluoro-piperidine-compounds (2016-11-15),

11. 9365654 - Anti-TrkA antibodies, derivatives and uses thereof (2016-06-14),

12. 9248115 - Silibinin component for the treatment of hepatitis (2016-02-02),

13. 9181279 - [object Object] (2015-11-10),

14. 9174977 - 2-azabicyclo[4.1.0]heptane derivatives as orexin receptor antagonists for the treatment of certain disorders (2015-11-03),

15. 9174966 - Crystalline forms of 6-(1H-imidazol-1-yl)-2-phenylquinazoline (2015-11-03),

Title: Innovations and Contributions of Lucio C Rovati

Introduction

Lucio C Rovati, an esteemed inventor based in Monza, Italy, has made significant contributions to the field of pharmaceuticals. With a remarkable portfolio of 55 patents, his innovative work focuses on developing compounds that have therapeutic applications, particularly in treating various pathologies.

Latest Patents

Among his most recent inventions is (R)-4-(1-(1-(4-(trifluoromethyl)benzyl)pyrrolidine-2-carboxamide)cyclopropyl)-benzoic acid, which serves as an EP4 receptor antagonist. This invention not only describes the compound itself but also advantageous methods for obtaining it, as well as pharmaceutical compositions containing this compound. Additionally, Rovati has developed a pharmaceutical combination that includes an EP4 antagonist and immune checkpoint inhibitors, aimed at enhancing treatment outcomes for tumors. This innovative combination, along with the polymorphic form A of the sodium salt of (R)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro[2.5]octane-5-carboxamido)cyclopropyl)benzoate, emphasizes his commitment to advancing cancer therapies.

Career Highlights

Throughout his career, Lucio C Rovati has had the opportunity to work with prominent companies such as Rottapharm Spa and Rotta Research Laboratorium S.p.a. His work in these organizations has been instrumental in advancing their pharmaceutical endeavors and expanding their research capabilities.

Collaborations

Collaboration has been a vital element of Rovati's career. He has worked alongside distinguished colleagues, including Francesco Makovec and Antonio Giordani. Together, they have driven innovative solutions and contributed to the pharmaceutical industry's evolution.

Conclusion

Lucio C Rovati's dedication to innovation and his substantive patent portfolio demonstrate his significant impact on pharmaceutical research and development. His latest inventions, career highlights, and collaborations reflect his unwavering commitment to advancing medical science, particularly in the fields of oncology and receptor antagonism. The contributions of inventors like Rovati continue to shape the future of healthcare and improve patient outcomes around the globe.

Profile summary based on public USPTO records.